Research programme: cannabidiol-based therapeutics - KannaLife SciencesAlternative Names: Cannabinoid-based antioxidants - KannaLife Sciences; Cannabinoid-based neuroprotectants - KannaLife Sciences; KLS-13019
Latest Information Update: 07 Mar 2016
At a glance
- Originator KannaLife Sciences
- Class Cannabinoids
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Brain injuries; Hepatic encephalopathy